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Abstract Myocardial ischemia/reperfusion injury is a
major cause of morbidity and mortality. The molecular
signaling pathways involved in cardiac protection from
myocardial ischemia/reperfusion injury are complex. An
emerging idea in signal transduction suggests the existence
of spatially organized complexes of signaling molecules in
lipid-rich microdomains of the plasma membrane known
as caveolae. Caveolins—proteins abundant in caveolae—
provide a scaffold to organize, trafﬁc, and regulate sig-
naling molecules. Numerous signaling molecules involved
in cardiac protection are known to exist within caveolae or
interact directly with caveolins. Over the last 4 years, our
laboratories have explored the hypothesis that caveolae are
vitally important to cardiac protection from myocardial
ischemia/reperfusion injury. We have provided evidence
that (1) caveolae and the caveolin isoforms 1 and 3 are
essential for cardiac protection from myocardial ischemia/
reperfusion injury, (2) stimuli that produce preconditioning
of cardiac myocytes, including brief periods of ischemia/
reperfusion and exposure to volatile anesthetics, alter the
number of membrane caveolae, and (3) cardiac myocyte-
speciﬁc overexpression of caveolin-3 can produce innate
cardiac protection from myocardial ischemia/reperfusion
injury. The work demonstrates that caveolae and caveolins
are critical elements of signaling pathways involved in
cardiac protection and suggests that caveolins are unique
targets for therapy in patients at risk of myocardial
ischemia.
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Introduction: A Role for Caveolae in Cardiac
Protection from Myocardial Ischemia/Reperfusion
Injury
Myocardial ischemia/reperfusion injury and resultant
myocardial infarction remains a major cause of death. One
of the most beneﬁcial experimental interventions to pro-
duce cardiac protection from myocardial ischemia/reper-
fusion injury is termed ischemic preconditioning (IPC)
[22]. IPC occurs when the myocardium is exposed to brief
(as short as 5 min) ischemia resulting in protection from
subsequent prolonged (up to 60 min) ischemia. IPC is a
biphasic event: The acute phase occurs immediately after
the IPC stimulus and lasts 1–3 h and is transient [19]. The
delayed phase of protection is seen 12–24 h after the initial
stimulus and lasts up to 72 h [21]. Cardiac protection in
which the cardiac protective strategy is applied at the time
of reperfusion has been termed postconditioning [40]. IPC
and postconditioning are promiscuous stimuli that involve
the initiation of many shared and interconnected signaling
pathways [10–12, 15] (Fig. 1). There is uncertainty as to
how signaling molecules interact within cells to produce
cardiac protection. We propose that the signal components
in cardiac protection coexist and function in a lipid-rich
environment (caveolae) and that the interaction of signal-
ing molecules with caveolins is necessary for cardiac
protection.
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and sphingolipid-enriched invaginations of the plasma
membrane [23] and are a subset of lipid rafts [29].
Caveolins—the structural proteins essential for caveolae
formation—are present in three isoforms [2, 24]. Caveolin-
1 and caveolin-2 (Cav-1 and Cav-2) are expressed in
multiple cell types, whereas caveolin-3 (Cav-3) is found
primarily in striated (skeletal and cardiac) muscle and
certain smooth muscle cells [33]. Caveolins are involved in
multiple cellular processes, including vesicular transport,
cholesterol and calcium homeostasis [8, 9, 14, 28, 31], and
signal transduction [3, 20, 34, 37]. Caveolins function as
chaperones and scaffolds via a scaffolding domain
recruiting signaling molecules to caveolae to provide direct
temporal and spatial regulation of signal transduction [32,
37]. Caveolins can inhibit proteins by interaction with a
caveolin-binding motif present in proteins, including eNOS
and ERK1/2 [5, 7, 16]. Alternatively, caveolins can pro-
mote signaling via enhanced receptor–effector coupling or
enhanced receptor afﬁnity when caveolins are upregulated
or overexpressed [6, 30, 38].
Preconditioning and postconditioning are mediated via a
complex molecular signaling cascade known as the reper-
fusion injury salvage kinase (RISK) pathway [12]. In
addition to sublethal ischemia and reperfusion, several
pharmaceuticals including opioids and volatile anesthetics
produce preconditioning and postconditioning via similar
signaling cascades [27]. Many RISK pathway molecules
associate with caveolae and caveolins, including G-protein
coupled receptors (GPCRs), receptor tyrosine kinases
(RTKs), Src kinases, G-proteins, H-Ras, nitric oxide syn-
thases, protein kinase C (PKC), phosphatidylinositol
3-kinase (PI3K), and MEK/ERK kinases (Fig. 2)[ 18].
Further evidence that caveolins are involved in cardiac
protection stems from the ﬁnding that infusion of the cave-
olin scaffolding domain peptide of Cav-1 into ischemic/
reperfused hearts increased the recovery of cardiac function
[39]. Subsequently, it was shown that ischemia/reperfusion
injury activated mitogen-activated protein kinases, redis-
tributed Cav-3, and downregulated expression of Cav-1,
limiting the negative impact of Cav-1 on eNOS [1]. This
suggested a potential mechanism for IPC via increased
generation of NO during lethal ischemia [4]. Others showed
that IPC can modulate the microenvironment of caveolae to
enrich for proteins that promote cardiac protection, includ-
ing eNOS and the glucose transporter GLUT-4 that trans-
locate to caveolae after IPC [17].
Caveolae and Caveolins are Essential for Cardiac
Protection from Ischemia/Reperfusion Injury
We ﬁrst set out to test the hypothesis that caveolae and
caveolins are critical elements of the signaling pathways
involved in cardiac protection from ischemia/reperfusion
injury. In a novel set of experiments, we investigated the
role of caveolae in IPC and opioid-receptor-mediated
Fig. 1 Overview of the signaling molecules involved in cardiac
protection. ROS reactive oxygen species, NO nitric oxide, GC
guanylyl cyclase (Adapted from [10])
Fig. 2 Signaling molecules involved in cardiac protection known to
localize in caveolae and interact with the scaffolding domain (green)
of caveolin
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adult rats we determined protein expression and localiza-
tion of the d-opioid receptor using coimmunohistochem-
istry, caveolar fractionation, and immunoprecipitations.
The d-opioid receptor colocalized in fractions with Cav-3
and could be immunoprecipitated by a Cav-3 antibody.
Immunohistochemistry conﬁrmed plasma membrane colo-
calization of the d-opioid receptor with Cav-3. Cardiac
myocytes were subjected to simulated ischemia (2 h) or an
IPC protocol (10 min ischemia, 30 min recovery, 2 h
ischemia) in the presence and absence of methyl-b-cyclo-
dextrin, which binds cholesterol and disrupts caveolae. We
also assessed the cardiac protective effects of SNC-121—a
selective d-opioid receptor agonist—on cardiac myocytes
with or without methyl-b-cyclodextrin and methyl-
b-cyclodextrin preloaded with cholesterol. Ischemia, sim-
ulated by mineral oil layering to inhibit gas exchange,
promoted cardiac myocyte cell death as assessed by trypan
blue staining—a response blunted by SNC-121 or by use of
the IPC protocol. Methyl-b-cyclodextrin treatment, which
disrupted caveolae (as detected by electron microscopy),
fully attenuated the protective effects of IPC or SNC-121,
resulting in cell death comparable to that of the ischemic
group. In contrast, protection was not blocked in cells
incubated with cholesterol-saturated methyl-b-cyclodex-
trin, which maintained caveolae structure and function.
These ﬁndings were the ﬁrst to suggest a key role for
caveolae, perhaps through enrichment of signaling mole-
cules, in contributing to cardiac protection from ischemia/
reperfusion injury.
We next investigated the role of caveolae and the spe-
ciﬁc caveolin molecules in cardiac protection. We tested
the hypothesis that caveolae and Cav-3 are essential for
volatile anesthetic-induced cardiac protection using cardiac
myocytes from adult rats and in vivo studies in Cav-3
knockout mice (Cav-3-/-)[ 13]. Cav-3-/- mice lack
Cav-3 and caveolae in their cardiac myocyte membranes.
We incubated normal adult rat cardiac myocytes with
methyl-b-cyclodextrin or colchicine to disrupt caveolae
formation and then exposed the myocytes to the volatile
anesthetic isoﬂurane for 30 min at 1.4%, followed by
simulated ischemia/reperfusion in a hypoxic chamber.
Isoﬂurane protected cardiac myocytes from simulated
ischemia/reperfusion, but this protection was abolished by
methyl-b-cyclodextrin or colchicine. Membrane fraction-
ation by sucrose density gradient centrifugation of myo-
cytes treated with methyl-b-cyclodextrin or colchicine
revealed that buoyant (caveolae-enriched) fractions had
decreased phosphoCav-1 and Cav-3 compared to control
cardiac myocytes. Cardiac protection in vivo was assessed
by measurement of infarct size relative to the area at risk
and cardiac troponin levels. Isoﬂurane induced a reduction
in infarct size and cardiac troponin relative to control.
Isoﬂurane-induced cardiac protection was abolished in
Cav-3-/- mice. We concluded that caveolae and Cav-3
were critical elements involved in volatile anesthetic-
induced cardiac protection from ischemia/reperfusion
injury.
We also explored a speciﬁc role for Cav-1 in cardiac
protection using in vitro and in vivo models of ischemia/
reperfusion injury, transgenic mice, and biochemical
assays [26]. We found that Cav-1 mRNA and protein were
expressed in adult mouse cardiac myocytes. The volatile
anesthetic isoﬂurane protected cardiac myocytes from
hypoxia-induced cell death. Hearts of wild-type (WT) mice
showed rapid phosphorylation of Src and Cav-1 after iso-
ﬂurane and ischemic preconditioning. The Src inhibitor
PP2 reduced phosphorylation of Src (Y416) and Cav-1 in
the heart and abolished isoﬂurane-induced cardiac protec-
tion in wild-type mice. Infarct size was reduced by iso-
ﬂurane in WT mice but not Cav-1-/- mice. Cav-1-/-
mice exposed to isoﬂurane showed signiﬁcant alterations in
Src phosphorylation and recruitment of C-terminal Src
kinase—a negative regulator of Src—when compared to
WT mice. The results indicated that activation of Src and
phosphorylation of Cav-1 are critical steps in the signaling
pathways involved in cardiac protection. Our recent study
indicates that delayed protection is still present in
Cav-1-/- but not Cav-3-/-, suggesting that the caveolae
formation (dependent on Cav-3) might be a common ele-
ment to both acute and delayed cardiac protection [36].
Overexpression of Cav-3 Produces Innate Cardiac
Protection from Ischemia/Reperfusion Injury
A key ﬁnding for our laboratories was that stimuli that can
invoke cardiac protection from ischemia/reperfusion injury
such as sublethal ischemia and volatile anesthetics actually
alter sarcolemmal membrane ultrastructure and increase
the number of formed caveolae (Fig. 3)[ 26, 35]. Given
these ﬁndings, we tested the hypothesis that cardiac myo-
cyte-speciﬁc overexpression of Cav-3 would enhance the
formation of caveolae and augment innate cardiac protec-
tion in vivo. We showed that adenovirus for Cav-3
increased caveolar formation and phosphorylation of sur-
vival kinases in cardiac myocytes in vitro. We then pro-
duced a transgenic mouse with cardiac myocyte-speciﬁc
overexpression of Cav-3 using the a-myosin heavy-chain
promoter (Cav-3 OE mice) and showed enhanced forma-
tion of caveolae on the cardiac myocyte sarcolemmal of
these mice. Cav-3 OE mice subjected to ischemia/reper-
fusion injury had a signiﬁcantly reduced infarct size rela-
tive to transgene-negative control mice. Innate cardiac
protection in Cav-3 OE mice was similar to WT mice
undergoing IPC and no increased protection was observed
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123in preconditioned Cav-3 OE mice. Additionally, Cav-3
knockout mice did not show innate protection and showed
no protection in response to preconditioning. Cav-3 OE
mouse hearts had increased basal Akt and GSK3b phos-
phorylation comparable to WT mice exposed to IPC.
Wortmannin—a PI3K inhibitor—attenuated basal phos-
phorylation of Akt and GSK3b and blocked cardiac pro-
tection in Cav-3 OE mice. Cav-3 OE mice had improved
functional recovery and reduced apoptosis at 24 h of
reperfusion following an initial 30 min of ischemia. We
concluded that expression of Cav-3 is both necessary and
sufﬁcient for cardiac protection and that increased
expression of caveolins has the potential to protect hearts
exposed to ischemia/reperfusion injury.
Conclusions
Cardiac protective strategies geared toward myocardial
ischemia/reperfusion injury are of major interest. It is now
clear that the caveolin protein family plays a diverse and
critical role in the cardiovascular system and a signiﬁcant
role in cardiac protective signaling. However, our under-
standing of the underlying mechanisms involved with
caveolae, caveolins, and cardiac protection remains limited
and an exciting area for active investigation. Further basic
science research and eventual randomized clinical trials are
needed to deﬁne the precise mechanisms and therapeutic
potential of caveolins in patients at risk of myocardial
ischemia.
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